IconOVir Bio

IconOVir Bio is a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus therapy for the treatment of cancer. Its proprietary oncolytic virus platform is based on technology developed by scientific founder Clodagh O'Shea, Ph.D., of the Salk Institute, and is designed to selectively replicate within and destroy tumor cells while sparing normal tissue. The company was founded by Two River Group, chaired by Arie Belldegrun, M.D., FACS — the team behind Kite Pharma and Allogene Therapeutics — and is focused on developing next-generation oncolytic viruses engineered for superior potency and immune engagement in solid tumors.